Short-term prediction of secondary progression in a sliding window: A test of a predicting algorithm in a validation cohort
Journal article, 2019

Introduction: The Multiple Sclerosis Prediction Score (MSPS, www.msprediction.com) estimates, for any month during the course of relapsing–remitting multiple sclerosis (MS), the individual risk of transition to secondary progression (SP) during the following year. Objective: Internal verification of the MSPS algorithm in a derivation cohort, the Gothenburg Incidence Cohort (GIC, n = 144) and external verification in the Uppsala MS cohort (UMS, n = 145). Methods: Starting from their second relapse, patients were included and followed for 25 years. A matrix of MSPS values was created. From this matrix, a goodness-of-fit test and suitable diagnostic plots were derived to compare MSPS-calculated and observed outcomes (i.e. transition to SP). Results: The median time to SP was slightly longer in the UMS than in the GIC, 15 vs. 11.5 years (p = 0.19). The MSPS was calibrated with multiplicative factors: 0.599 for the UMS and 0.829 for the GIC; the calibrated MSPS provided a good fit between expected and observed outcomes (chi-square p = 0.61 for the UMS), which indicated the model was not rejected. Conclusion: The results suggest that the MSPS has clinically relevant generalizability in new cohorts, provided that the MSPS was calibrated to the actual overall SP incidence in the cohort.

Epidemiology

progressive

multiple sclerosis

relapsing/remitting

outcome measurement

Author

Bengt Skoog

University of Gothenburg

J. Link

Karolinska Institutet

Helen Tedeholm

University of Gothenburg

Marco Longfils

Chalmers, Mathematical Sciences, Applied Mathematics and Statistics

Olle Nerman

Chalmers, Mathematical Sciences, Applied Mathematics and Statistics

J Fagius

Uppsala University

Oluf Andersen

University of Gothenburg

Multiple Sclerosis Journal - Experimental, Translational and Clinical

20552173 (eISSN)

Vol. 5 3

Subject Categories

Urology and Nephrology

Rheumatology and Autoimmunity

Cardiac and Cardiovascular Systems

DOI

10.1177/2055217319875466

More information

Latest update

1/31/2022